Article Text

Download PDFPDF
Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells
  1. Yefang Xu, MD*,
  2. Jingjing Zhang, MD*,
  3. Jing Wu, PhD,
  4. Sheng Zhong, PhD and
  5. Hongxia Li, PhD*
  1. *Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, Haidian District, Beijing, China;
  2. Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN; and
  3. Municipal Key Laboratory of Child Development and Nutriomics, Capital Institute of Pediatrics, Beijing, China.
  1. Address correspondence and reprint requests to Hongxia Li, PhD, Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, 10 Tieyi Rd of Haidian District, Beijing, 100038, China. E-mail: Lihx69{at}hotmail.com; Sheng Zhong, PhD, Municipal Key Laboratory of Child Development and Nutriomics, Capital Institute of Pediatrics, Yabao Rd of Chaoyang District, Beijing, 100020, China. E-mail: seng_zhong{at}yahoo.com.hk.

Abstract

Objective Resistance to chemotherapy is a major factor that limits the postsurgical survival of ovarian cancer patients. Janus-activated kinase 2 (JAK2) has been implicated in cancer cell survival and the development of drug resistance in ovarian cancers. In the present study, we sought to determine whether inhibition of JAK2 reverses drug resistance in OC3/TAX300 cells, a paclitaxel-resistant human ovarian cancer cell line previously established in our laboratory.

Methods OC3/TAX300 cells were transduced with lentivirus expressing small interference RNA (siRNA) against JAK2 and treated with JAK2 kinase inhibitor AG490.

Results Treatment with JAK2-siRNA markedly decreased the messenger RNA and protein of JAK2 as determined by real-time polymerase chain reaction and Western blot analysis. OC3/TAX300 cells treated with JAK2-siRNA exhibited stalled growth, increased cell cycle arrest in G2/M phase, and enhanced apoptosis in response to paclitaxel. In keeping with this, JAK2-siRNA also inhibited the expression of multidrug resistance protein 1. To determine whether JAK2 promotes paclitaxel resistance via phosphorylation of signal transducer and activator of transcription 3 (STAT3), a transcription factor known to be involved in resistance to chemotherapy, we treated OC3/TAX300 cells with JAK2 kinase inhibitor AG490. Of note, AG490 reduced the level of p-STAT3 and inhibited the expression of multidrug resistance protein 1 in a dose-dependent manner.

Conclusions Collectively, we conclude that the JAK2-STAT3 pathway promotes the development of paclitaxel resistance via upregulating the expression of prosurvival and antiapoptotic genes. Targeting this pathway may be effective in reversing resistance to chemotherapy in ovarian cancers.

  • Ovarian cancer
  • Paclitaxel resistance
  • JAK2-STAT3
  • RNA interference

Statistics from Altmetric.com

Footnotes

  • Hongxia Li and Sheng Zhong are considered corresponding coauthors.

  • This work was supported by the National High Technology Research and Development Program of China (grant no. 2006AA02A245).

  • The authors declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.